This patient (female, ex-smoker, with BRAF-G446V mutation NSCLC, 65 years of age) had progressed after four prior lines of therapy (Supplementary Table S2), including BRAF/MEK inhibitors dabrafenib/trametinib and anti–PD-1 nivolumab (best response of SD), the latter of which the patient received 14 months prior to enrollment. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.